Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Rectal Neoplasms × Diathermy × Clear all

Phase

Phase 3 3 Phase NA 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 2 Hyperthermia 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Rectal Neoplasms 1 Colonic Neoplasms 1

Interventions

Oxaliplatin 20 Capecitabine 16 Fluorouracil 15 Irinotecan 11 Radiotherapy 10 Leucovorin 8 Cetuximab 6 Bevacizumab 6 Gemcitabine 5 oblimersen 3 fludarabine 3 aldesleukin 3 Nivolumab 3 Erlotinib Hydrochloride 3 Cyclophosphamide 3 labetuzumab 2 dehydroftorafur 2 conatumumab 2 Receptor Protein-Tyrosine Kinases 2 Radiation 2 Panitumumab 2 Neoadjuvant Therapy 2 Gefitinib 2 Diphenhydramine 2 5,10-methylenetetrahydrofolic acid 2 sintilimab 1 sargramostim 1 rilotumumab 1 pertuzumab 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01716949 2017-08-11

HyRec

University of Erlangen-Nürnberg Medical School

Phase 1/2 Unknown

Gastrointestinal

Hyperthermia, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡